"The Closed Loop of BioProtocol Valuation and Scientific Progress: My Green Light Criteria" 1. First, look at the mechanism: @BioProtocol transforms informed consent, IP, and wet lab experiments into on-chain receipts; Ignitions connects pre-registered endpoints with differential batch funding + replication thresholds, with unused portions flowing back; Stake $BIO → mint veBIO; BioXP decays over time, bringing active contributors to the forefront. 2. Next, consider the payment model: @NEURONGale centers on "paying for work," allocating 60-70% to contributors (BioXP/veBIO/wet lab/data room), 15-20% for liquidity, 10-15% for the team (linear over 2 years), and 5-10% for R&D; surplus is burned/reserved based on milestones, tightly binding this allocation to scientific replication. 3. Market signals: $BIO is approximately 81% below TGE FDV, with cumulative staking of over 2.1M; on the funding side, there is a 6.9M seed round led by Maelstrom as a safety net, with narrative and runway coexisting. My approach: anchor the implied FDV I am willing to hold post-listing; expand positions after the first batch of replication receipts is realized. 4. Pipeline and cash flow: BioAgents have begun generating multi-source hypotheses and bridging to wet lab experiments; valuation can be tested using "replicable Assay pipeline × receipt density" discounted, cross-validated with FDV sanity. What is your "green light" criterion? 1) Overfunding speed 2) Reasonableness of FDV 3) Replication pass rate 4) Assay revenue Feel free to quote/comment with your $BIO pricing method, and you can also refer to @vita_dao's progress in Bio. #DeSci #BioProtocol